Stifel has maintained its "Buy" rating on Revolution stock, setting a price target of $215. This decision comes in light of recent trial data that the firm considers favorable for the company's prospects. The analysis reflects confidence in Revolution's performance and potential growth based on the outcomes of the ongoing clinical trials.
Related Articles
Don't miss out on breaking stories and in-depth articles.